Blog
RSS FeedPosted by Michael Wonder on 05 Mar 2020
The U.S. has a problem with prescription drug prices. Canada shouldn’t try to fix it.
2 March 2020 - President Donald Trump and the U.S. Congress are scrambling to find ways to make medicines more ...
Posted by Michael Wonder on 20 Feb 2020
Canadian regulator considers changes to new drug pricing plan
20 February 2020 - Canada’s drug pricing agency is contemplating significant changes to how it will apply new regulations aimed at ...
Posted by Michael Wonder on 13 Feb 2020
The grass is the same colour, part II: prescription drug woes on both sides of the US-Canada border
13 February 2020 - Which industrialised nation with a fractured health care system and a divided government is having a high-stakes ...
Posted by Michael Wonder on 09 Feb 2020
Extreme regulations to lower drug prices mean Canada will get fewer new drugs
7 February 2020 - Severe price cuts would clearly discourage pharmaceutical manufacturers from launching new drugs in Canada. ...
Posted by Michael Wonder on 05 Feb 2020
Pharma execs argue new Canadian regulations for setting drug prices will hurt the country
4 February 2020 - As Canada gets set to implement new regulations designed to cut prescription drug spending, the pharmaceutical ...
Posted by Michael Wonder on 25 Nov 2019
Proposed Ontario drug regulation changes worry policy experts
22 November 2019 - The Ontario government is proposing drug regulation changes that it says will remove red tape and ...
Posted by Michael Wonder on 29 Oct 2019
Costly prescription eye treatment highlights a loophole in Canada’s drug-price regulation process
28 October 2019 - The Ontario government has begun covering $100,000-a-year eye drops for an ultrarare disease, bringing relief to ...
Posted by Michael Wonder on 17 Oct 2019
Canadian breakthrough that became the world's most expensive drug, then vanished, gets second chance
17 October 2019 - CBC story about how pharmaceutical industry abandoned gene therapy Glybera sparks NRC effort to re-invent it. ...
Posted by Michael Wonder on 24 Sep 2019
Institutional investors urging Congress to vote down CUSMA, citing effect on drug prices
23 September 2019 - A group of institutional investors representing more than US$500 billion is calling on the U.S. Congress ...
Posted by Michael Wonder on 12 Sep 2019
New rules will keep the best medications from desperate Canadians
12 September 2019 - One reaction to recent amendments to the rules of the federal Patented Medicine Prices Review Board, ...
Posted by Michael Wonder on 10 Sep 2019
Canada releases final amendments to patented medicines pricing regulations
9 September 2019 - On 9 August 2019 Health Canada announced the final amendments to the Patented Medicines Regulations. ...
Posted by Michael Wonder on 08 Sep 2019
Trudeau’s drug price overhaul is set to cost drug makers billions
6 September 2019 - Canada revamps drug-pricing regime for first time since 1987. ...
Posted by Michael Wonder on 26 Aug 2019
Drug-price reforms need not affect research on rare diseases – or the Canadians who have them
26 August 2019 - On 9 August, the Patented Medicine Prices Review Board of Canada announced new drug-pricing regulations for ...
Posted by Michael Wonder on 24 Aug 2019
Companies file suit in Canada challenging new rules to lower drug prices
23 August 2019 - Five pharmaceutical companies said on Friday they have filed a complaint in a Canadian court challenging ...
Posted by Michael Wonder on 21 Aug 2019
Empirical evidence supports critics of Patented Medicine Prices Review Board regulations
21 August 2019 - Canadian Health Policy Institute, a Toronto-based private-sector think-tank established in 2012, has published several studies that bolster ...